{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:30:41Z","timestamp":1777923041144,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:p>\n                    The main objective of this study was to compare\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activities of a novel fluoroquinolone (FQ), UB-8902, with ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MOX) against\n                    <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                    isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. The concentrations studied ranged from 0.125 to 128\u2009\u03bcg\/mL in twofold dilutions. UB-8902 was more active than LFX and similar to MOX for OFX-resistant\n                    <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                    isolates. In addition, UB-8902 and MOX showed equal activity against drug-susceptible isolates, both being more active than OFX and LFX. In conclusion, the new FQ, UB-8902, showed good activity against OFX-resistant isolates. Moreover, it showed better activity than OFX and LFX and was equivalent to MOX against FQ-susceptible clinical isolates. UB-8902 can be considered as a drug with potential antituberculous activity, similar to MOX.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0367","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T11:31:05Z","timestamp":1583926265000},"page":"1019-1022","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["<i>In Vitro<\/i>\n                    Activity of a Novel Quinolone, UB-8902, Against Ofloxacin-Resistant\n                    <i>Mycobacterium tuberculosis<\/i>\n                    Isolates"],"prefix":"10.1177","volume":"26","author":[{"given":"Griselda","family":"Tud\u00f3","sequence":"first","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Lopez-Gavin","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Portell-Buj","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Freixes","sequence":"additional","affiliation":[{"name":"Cenavisa Plc Laboratories, Reus, Tarragona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angely","family":"Roman","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa","family":"Mont\u00e9","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Gonzalez-Martin","sequence":"additional","affiliation":[{"name":"Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"Geneva","article-title":"Global Tuberculosis Report 2018","author":"World Health Organization,","year":"2018","unstructured":"World Health Organization,. 2018. Global Tuberculosis Report 2018. WHO\/CDS\/TB\/2018.20. WHO, Geneva.","journal-title":"WHO\/CDS\/TB\/2018.20"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073611"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00695-11"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1043-y"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00671-6"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7915.2008.00063.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.02.013"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.06.006"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.08.004"},{"key":"e_1_3_4_11_2","unstructured":"World Health Organization. 2018. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. WHO\/CDS\/TB\/2018.24. WHO Geneva."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.773"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2009.11.014"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9869"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr173"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120470"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00287-09"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1768"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-78"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:36:46Z","timestamp":1777667806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2019.0367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1089\/mdr.2019.0367"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0367","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}